Impact of Postoperative Chemotherapy on Survival in Patients with Primary Central Nervous System Lymphoma: A Study Based on the SEER Database

被引:0
作者
Chen, Yushan [1 ,2 ]
Zheng, Shuishun [3 ]
Zheng, Shunyong [1 ]
Lin, Hong [3 ]
Wei, Lizhen [1 ]
Chen, Shaoqiang [4 ]
机构
[1] Zhangzhou Hosp, Imaging Dept, Zhangzhou, Fujian, Peoples R China
[2] Fujian Med Univ, Imaging Dept, Zhangzhou Affiliated Hosp, Zhangzhou, Fujian, Peoples R China
[3] Zhangzhou Hosp, Neurosurg Dept, Zhangzhou, Fujian, Peoples R China
[4] Fujian Med Univ, Sch Basic Med Sci, Fuzhou, Fujian, Peoples R China
关键词
postoperative chemotherapy; overall survival; primary central nervous system lymphoma; SEER; HIGH-DOSE METHOTREXATE; PRIMARY CNS LYMPHOMA; MALIGNANT-LYMPHOMA; PROGNOSTIC MODEL; EPIDEMIOLOGY; SURVEILLANCE; MANAGEMENT; RITUXIMAB; DIAGNOSIS; THERAPY;
D O I
10.12968/hmed.2024.0243
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims/Background We aimed to investigate the impact of postoperative chemotherapy (POCT) on survival in patients with primary central nervous system lymphoma (PCNSL) using data from the Surveillance, Epidemiology, and End Results (SEER) database. Methods This study included 786 PCNSL patients, of which 605 received chemotherapy after surgery, and 181 did not. Data from the SEER registry database (2007-2020) were used to analyze PCNSL. Baseline information, including age, sex, race, marital status, primary tumour site, histological type, summary stage, surgical procedures, chemotherapy, and radiotherapy, was analyzed. Propensity Score Matching (PSM) (1:1) was employed to balance the effects of confounding variables between the two groups. Subsequently, Cox regression and bidirectional stepwise regression were used to identify independent prognostic factors. Kaplan-Meier (K-M) survival curves were constructed to assess the impact of POCT on patient prognosis. Additionally, two cases of PCNSL with typical magnetic resonance imaging appearances were presented. Results Multivariate Cox regression results revealed that age older than 60 years (hazard ratio [HR] = 1.786; 95% confidence interval [CI]: 1.272-2.509; p = 0.001) and absence of POCT (HR = 2.841; 95% CI: 2.159-3.738; p < 0.001) were independent prognostic risk factors, while primary tumour locations in the meninges (HR = 0.136; 95% CI: 0.032-0.569; p = 0.006) and other nervous system regions (HR = 0.552; 95% CI: 0.326-0.936; p = 0.027), as well as histological morphologies such as diffuse large B-cell lymphoma (HR = 0.233; 95% CI: 0.128-0.425; p < 0.001) and non-Hodgkin lymphoma (HR = 0.559; 95% CI: 0.356-0.876; p = 0.011), were associated with favourable patient outcomes. K-M curves demonstrated that the group undergoing POCT had a significantly more favourable prognosis compared to the non-POCT group, before (HR = 0.454; 95% CI: 0.343-0.600; p < 0.0001) or after PSM (HR = 0.580; 95% CI: 0.431-0.780; p < 0.0001). For patients with PCNSL, those with tumours located in the infratentorial region (HR = 0.231; 95% CI: 0.078-0.682; p = 0.046), supratentorial region (HR = 0.250; 95% CI: 0.163-0.383; p < 0.0001), overlapping brain regions (HR = 0.201; 95% CI: 0.056-0.727; p = 0.0058), and those who underwent biopsy (HR = 0.740; 95% CI: 0.463-1.182; p = 0.003), subtotal resection (STR) (HR = 0.490; 95% CI: 0.265-0.906; p = 0.0064), or gross total resection (GTR) (HR = 0.613; 95% CI: 0.292-1.287; p = 0.0003) had better prognoses in the postoperative chemotherapy group compared to the non-chemotherapy group. Conclusion POCT significantly improves the prognosis of PCNSL patients and identifies the characteristics of the benefiting population. This information aids clinical practitioners in designing personalized treatment plans for individuals and advancing precise treatment.
引用
收藏
页数:22
相关论文
共 50 条
  • [21] Updates of primary central nervous system lymphoma
    Wu, Jiaying
    Zhou, Delian
    Zhu, Xiaojian
    Zhang, Yicheng
    Xiao, Yi
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2024, 15
  • [22] Challenges in the treatment of elderly patients with primary central nervous system lymphoma
    Roth, Patrick
    Khe Hoang-Xuan
    CURRENT OPINION IN NEUROLOGY, 2014, 27 (06) : 697 - 701
  • [23] Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma
    Sun, Xuefei
    Liu, Jing
    Wang, Yaming
    Bai, Xueyan
    Chen, Yuedan
    Qian, Jun
    Zhu, Hong
    Liu, Fusheng
    Qiu, Xiaoguang
    Sun, Shengjun
    Ji, Nan
    Liu, Yuanbo
    ONCOTARGET, 2017, 8 (30) : 49156 - 49164
  • [24] Epidemiology, Tumor Characteristics, and Survival in Patients With Primary Pancreatic Lymphoma A Large Population-based Study Using the SEER Database
    Mukhija, Dhruvika
    Nagpal, Sajan Jiv Singh
    Sohal, Davendra P. S.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2019, 42 (05): : 454 - 458
  • [25] Impact of maintenance rituximab on duration of response in primary central nervous system lymphoma
    Ambady, Prakash
    Fu, Rongwei
    Szidonya, Laszlo
    Peereboom, David M.
    Doolittle, Nancy D.
    Neuwelt, Edward A.
    JOURNAL OF NEURO-ONCOLOGY, 2020, 147 (01) : 171 - 176
  • [26] Survival prediction and conditional survival of primary central nervous system lymphoma: A population-based study
    Ke, Boxi
    Cai, Xueli
    Peng, Xiao
    JOURNAL OF CLINICAL NEUROSCIENCE, 2021, 93 : 188 - 194
  • [27] Primary central nervous system lymphoma: Retrospective analysis of 34 cases in a single centre
    Wang, Huafeng
    Wang, Ming
    Wei, Juying
    Wang, Lei
    Mao, Liping
    Jin, Jie
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2018, 46 (02) : 883 - 894
  • [28] Primary Central Nervous System Lymphoma
    Doucet, Stephane
    Kumthekar, Priya
    Raizer, Jeffrey
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2013, 14 (02) : 185 - 197
  • [29] Primary Central Nervous System Lymphoma
    Sinicrope, Kaylyn
    Batchelor, Tracy
    NEUROLOGIC CLINICS, 2018, 36 (03) : 517 - +
  • [30] Primary central nervous system lymphoma
    Citterio, Giovanni
    Reni, Michele
    Gatta, Gemma
    Ferreri, Andres Jose Maria
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2017, 113 : 97 - 110